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Key Messages

Vitamin A deficiency is associated with increased mortality from infectious diseases, and to prevent vitamin A deficiency, high-dose vitamin A capsules are recommended twice per year to children between 6 months and 5 years of age in more than 100 countries considered at risk of vitamin A deficiency.The effect of vitamin A supplementation is assumed to be always beneficial, reducing deaths due to vitamin A deficiency.A number of observations contradict the interpretation that vitamin A supplementation acts merely to prevent vitamin A deficiency. The effect of vitamin A supplementation is not associated with the degree of deficiency, and the effect is modified by factors unrelated to deficiency, such as sex of the child and the vaccines he or she has received.The existing evidence supports that besides preventing vitamin A deficiency, vitamin A supplementation also has long-lasting immunological effects; and, worryingly, the effect of vitamin A supplementation may be harmful in some subgroups.To create optimal vitamin A supplementation policies, we urgently need to re-assess the effect of vitamin A supplementation in large-scale RCTs powered to study effect modification by sex and other potential effect modifiers, and with nested immunological studies.

Introduction: the vitamin A enigma
==================================

Vitamin A deficiency (VAD) was common in high-income countries around the time of World War II, and in low-income countries in the mid-1980s, and attentive clinicians observed that this condition was linked to increased overall morbidity and mortality.[@dyv117-B1]

In the late 1980s and early 1990s, eight randomized controlled trials (RCTs) of vitamin A supplementation (VAS) were conducted in low-income countries.[@dyv117-B2] Six showed marked effects on overall mortality of providing VAS. The RCTs which showed the strongest effect were two from India and Indonesia using smaller weekly[@dyv117-B3] doses or daily dosing through fortification;[@dyv117-B4] the other RCTs used high-dose supplements. Two high-dose RCTs from India[@dyv117-B5] and Sudan[@dyv117-B6] found no effect.

A meta-analysis of these eight original RCTs was conducted and concluded that VAS---including the two studies with no effect--- reduced overall mortality by 23%.[@dyv117-B2] The *P*-value for homogeneity of effects across the RCTs was 0.088 and reasons for the variation in effect were explored.[@dyv117-B2] It was concluded that the variation was not explained by the degree of underlying VAD, nor by sex or age at supplementation.[@dyv117-B2] WHO-recommended programmes providing high-dose VAS twice per year to children aged between 6 months and 5 years became widespread[@dyv117-B7] and are still carried out in more than 100 countries considered at risk of VAD.[@dyv117-B8]

The common interpretation is that VAD is associated with increased mortality---and that VAS works by preventing and treating VAD. The lack of effect in two of the original eight trials and the lack of association between the degree of VAD and the effect of VAS should perhaps have raised concern about this compelling but rather simple interpretation. After the eight original RCTs, there have been few RCTs of VAS to children above 6 months of age; once an intervention becomes policy, it is considered unethical to test it in RCTs, since these imply depriving some children of a recommended intervention.

There have been numerous RCTs carried out to test whether the observed beneficial effects of VAS could be extended to younger children. Most RCTs providing VAS to children between 1 and 5 months of age found no beneficial effects of providing VAS, even when VAD was prevalent (reviewed in[@dyv117-B9]). Several RCTs of neonatal VAS (NVAS) have yielded conflicting results.[@dyv117-B10] Very recently, three WHO-commissioned RCTs of NVAS from Ghana,[@dyv117-B11] Tanzania[@dyv117-B12] and India[@dyv117-B13] were individually powered to show a 15% reduction in mortality by 6 months of age, but found no overall benefit; the random effect meta-analysis estimate of these three trials by 6 months of age and 12 months of age being 1.03 \[95% confidence interval (CI) 0.88-1.19) and 1.02 (0.92-1.13), respectively. Furthermore, two new large RCTs of VAS to children above 6 months of age in Guinea-Bissau and India found no overall beneficial effect of VAS.[@dyv117-B14]^,^[@dyv117-B15]

All RCTs except one[@dyv117-B14] hypothesized that the overall effect of VAS would be beneficial. Hence, when so many recent RCTs produce unexpected results there is reason to pause and reflect. Moreover, many of the RCTs found interactions between VAS and various background factors. Noteworthy, VAS was even more beneficial than anticipated in some subgroups, but worryingly associated with negative effects in other subgroups. The subgroup analyses have usually been dismissed as *post hoc* analyses. However, since VAS is being provided to millions of children with little or no assessment of the effect, it should be a concern when our expectations of universal beneficial effects are contradicted and potential explanations should be pursued.

We therefore reviewed the factors which may modify the effect of VAS on mortality, the strength of evidence and potential underlying biological explanations, to inspire further discussion and inform future studies to define optimal policies.

Methods and Results
===================

We reviewed the existing literature on the mortality effect of high-dose VAS to children aged above 6 months and to neonates, respectively. For studies in children aged above 6 months, we used as a starting point the meta-analysis of RCTs in children above 6 months of age conducted in 1993,[@dyv117-B2] adding subsequent large RCTs which reported mortality as the main outcome. For studies in neonates, we included all available RCTs. Data are presented separately for the two age groups unless not relevant.

Potential modifiers of the effect of VAS
----------------------------------------

Potential modifiers of the effect of VAS are summarized in [Table 1](#dyv117-T1){ref-type="table"}. Table 1.Potential effect modifiers of high-dose vitamin A supplementationPotential modifierEffectVitamin A deficiencyNo strong data support that VAD is an important effect modifier of VASSexVAS in early infancy may have a less beneficial effect for females than for males, at least in settings with no maternal VAS and low HIV prevalence, where children receive first BCG and then DTP. The evidence in older children is less clearVaccinesVAS given close in time to DTP vaccine seems to be associated with increased female mortality. In contrast, VAS given close in time to measles vaccine may benefit females more than males. The combination of VAS, a live and an inactivated vaccine may be harmful for malesRepeated vitamin AThere is some evidence to suggest that a first dose of VAS primes for a beneficial response to subsequent doses of VAS in femalesLength of follow-upLength of follow-up is an important indicator of other exposures and may modify the effect of VAS depending on the nature of these other exposuresBirthweightThe interaction between VAS and birthweight has been inconsistent and seem more likely to be explained by confoundingSeasonSeason is a potential effect modifier of VAS, which may be linked to pathogen exposure and could provide clues about the biological mechanisms behind the variable effect of VAS

### Vitamin A deficiency

According to current understanding, VAD should be a strong modifier of the effect of VAS on mortality: a beneficial effect of VAS should be seen in populations suffering from VAD and the effect should be stronger with increasing prevalence of VAD, whereas no effect is expected in populations with adequate vitamin A status.

#### VAS above 6 months of age

The assessment of the importance of VAD for the effect of VAS is hampered by the lack of good indicators of VAD and the fact that studies have collected different indicators. However, most of the original eight RCTs in children above 6 months of age were conducted in populations where xerophthalmia, a quite unequivocal clinical indicator of VAD, was present.[@dyv117-B2] There was no indication in these RCTs that the effect of VAS depended on the prevalence of VAD in the population.[@dyv117-B2] For instance, no effect of VAS was seen in India where around 6% of the children suffered from xerophthalmia,[@dyv117-B5] whereas a 19% (2--32%) mortality reduction was seen in Ghana, where less than 1% had signs of xerophthalmia[@dyv117-B16] ([Figure 1](#dyv117-F1){ref-type="fig"}). In two subsequent RCTs from the 1990s, there was again no strong association between the effect of VAS and degree of underlying VAD.[@dyv117-B17]^,^[@dyv117-B18] In the two new RCTs in children above 6 months of age, the Indian RCT was conducted in a population with 3.5% of control children having Bitot's spots, a clinical manifestation of xerophthalmia.[@dyv117-B15] The Guinea-Bissau RCT was conducted in a population with no xerophthalmia but more than 60% of the children having low levels of serum retinol-binding protein.[@dyv117-B19] None of these studies found overall beneficial effects ([Figure 1](#dyv117-F1){ref-type="fig"}). Figure 1.The relative risk comparing vitamin A vs no vitamin A by prevalence of xerophthalmia in the original eight, the two subsequent, and the two new trials of vitamin A supplementation to children above 6 months of age[@dyv117-B2]^,^[@dyv117-B14]^,^[@dyv117-B15]^,^[@dyv117-B17]^,^[@dyv117-B18] (modified from Beaton *et al.*[@dyv117-B2]).

#### NVAS

NVAS has been interpreted to be most beneficial in populations with potential VAD as assessed by maternal night blindness, but not all trials have data and the results are not consistent. For instance, the RCT showing the strongest effect was conducted in Indonesia in a setting with no maternal VAD. Baseline mortality has been used as an indicator of VAD, and was available for all trials. As seen from [Figure 2](#dyv117-F2){ref-type="fig"}, the effect of NVAS is not more beneficial with higher baseline mortality rate in the control group. Figure 2.The effect of neonatal vitamin A supplementation by control group mortality.[@dyv117-B11]^,^[@dyv117-B20]^,^[@dyv117-B22]^,^[@dyv117-B23]^,^[@dyv117-B25]^,^[@dyv117-B26]^,^[@dyv117-B36]^,^[@dyv117-B37]^,^[@dyv117-B47]^,^[@dyv117-B70].

#### Conclusion

Though the interpretation should be cautious due to the lack of good indicators of VAD (apart from xerophthalmia), there are no strong data to support that VAD is an important modifier of the effect of VAS on mortality. If anything, the total body of evidence ([Figures 1](#dyv117-F1){ref-type="fig"} and [2](#dyv117-F2){ref-type="fig"}) contradicts the current interpretation that the overall effect of VAS on mortality is explained by prevention and treatment of VAD.

### Sex of the child

#### VAS above age 6 months

The original eight RCTs which stratified data by sex reported no evidence of sex-differences in the response to VAS.[@dyv117-B2] Of the two new RCTs, the Indian RCT found no sex differences but the Guinea-Bissau RCT, in which VAS was provided with vaccines, found a strong interaction between VAS and sex, with a more beneficial effect in females than in males[@dyv117-B14] ([Table 2](#dyv117-T2){ref-type="table"}). Noteworthy, in this RCT there were no sex differences in vitamin A status at enrolment.[@dyv117-B19] Table 2.Estimates of the effect of vitamin A supplementation on mortality by age group and sexAuthor, country and year of publicationOverall effect estimate(95% CI)MalesFemales**At-birth supplementation**Humphrey, Indonesia 1996[@dyv117-B22]0.36 (0.16--0.87)0.15 (0.03--0.68)0.84 (0.26--2.77)Rahmatullah, India 2003[@dyv117-B2] [@dyv117-B3]0.78 (0.63--0.96)0.70 (0.52--0.94)0.87 (0.65--1.17)Benn, Guinea-Bissau 2008[@dyv117-B3] [@dyv117-B6]1.07 (0.79--1.44)0.84 (0.55--1.27)1.39 (0.90--2.14)Klemm, Bangladesh 2008[@dyv117-B4] [@dyv117-B7]0.85 (0.73--1.00)0.89 (0.72--1.10)0.81 (0.65--1.00)[\*](#dyv117-TF2){ref-type="table-fn"}Benn, Guinea-Bissau 2010[@dyv117-B3] [@dyv117-B7]1.08 (0.79--1.47)0.74 (0.55--1.22)1.42 (0.94--2.15)Kirkwood, Zimbabwe 2010[@dyv117-B2] [@dyv117-B4]Not provided1.19 (1.00--1.42)0.93 (0.78--1.14)[\*](#dyv117-TF2){ref-type="table-fn"}\#Benn, Guinea-Bissau 2014[@dyv117-B20]1.28 (0.91--1.81)1.35 (0.84--2.16)1.21 (0.73--2.01)Edmond, Ghana 2014[@dyv117-B11]1.13 (0.98--1.31)1.19 (0.97--1.47)1.08 (0.87--1.34)[\*\*](#dyv117-TF4){ref-type="table-fn"}Masanja, Tanzania, 2014[@dyv117-B1] [@dyv117-B2]1.04 (0.93--1.17)0.96 (0.82--1.12)1.16 (0.97--1.38)[\*\*](#dyv117-TF4){ref-type="table-fn"}Mazumder, India 2014[@dyv117-B1] [@dyv117-B3]0.94 (0.86--1.02)0.94 (0.82--1.08)0.93 (0.83--1.05)**1-11 months**Pathwardhan, Jordan 1966[@dyv117-B71]0.50 (0.13--1.94)0 (one placebo death)0.59 (0.15--2.30)Sommer, Indonesia 1986[@dyv117-B72]0.83 (0.51--1.37)0.59 (0.33--1.06)1.06 (0.62--1.81)West, Nepal 1995[@dyv117-B70]1.11 (0.86--1.42)1.24 (0.86--1.78)0.98 (0.68--1.42)Mahalanabis, Bangladesh 1997[@dyv117-B73]1.06 (0.52--2.18)0.70 (0.21--2.36)1.40 (0.59--3.34)Fisker, Guinea-Bissau 2014[@dyv117-B1] [@dyv117-B4] [\*\*\*](#dyv117-TF2){ref-type="table-fn"}0.73 (0.44--1.22)1.22 (0.57--2.61)0.46 (0.22--0.97)**12 months+**Sommer, Indonesia 1986[@dyv117-B72]0.66 (0.44--0.97)0.59 (0.37--0.95)0.80 (0.46--1.40)West, Nepal, 1991[@dyv117-B4] [@dyv117-B6]0.70 (0.57--0.87)0.77 (0.55--1.09)0.65 (0.48--0.89)Daulaire, Nepal 1992[@dyv117-B74]0.74 (0.55--0.99)0.72 (0.48--1.08)0.76 (0.48--1.19)Herrera, Sudan 1992[@dyv117-B6]1.06 (0.82--1.37)1.25 (0.85--1.83)0.93 (0.66--1.31)Ghana Vast Study Team, Ghana 1993[@dyv117-B1] [@dyv117-B6]0.81 (0.68--0.98)0.73 (0.59--0.92)0.90 (0.71--1.15)Awasthi, India 2013[@dyv117-B1] [@dyv117-B5]0.96 (0.89--1.03)0.99 (0.91--1.07)0.93 (0.86--1.00)Fisker, Guinea-Bissau 2014[@dyv117-B1] [@dyv117-B4] [\*\*\*](#dyv117-TF5){ref-type="table-fn"}1.68 (0.70--4.06)10.7 (1.37--83.6)0.43 (0.11--1.66)[^1][^2][^3][^4][^5]

#### NVAS

Two of the three RCTs in Guinea-Bissau found that males benefited more than females from NVAS. In a combined analysis of the three Guinea-Bissau RCTs, NVAS tended to reduce infant mortality in males, but was associated with 35% (95% CI 4-75%) higher infant mortality in females (*P* = 0.01 for interaction between NVAS and sex).[@dyv117-B20] Vitamin A status was assessed in one of these RCTs and, if anything, males had better vitamin A status than females.[@dyv117-B21]

Similar tendencies with a better effect of NVAS in males were seen in the RCTs from Indonesia, India 2003 and Tanzania[@dyv117-B12]^,^[@dyv117-B22]^,^[@dyv117-B23] ([Table 2](#dyv117-T2){ref-type="table"}). In contrast, in the RCTs from Zimbabwe and Ghana the effect tended to be worse for males. In a sex-stratified analysis of the total study population in the Zimbabwe RCT, NVAS was associated with 19% (0-42%) increased mortality in males.[@dyv117-B24] However, the Zimbabwean RCT was a 2-by-2 factorial trial with maternal post-partum VAS and NVAS, conducted in a population with a very high HIV prevalence. The mortality analysis was mainly driven by deaths among children of HIV-infected mothers,[@dyv117-B25]^,^[@dyv117-B26] and significantly more of these HIV-related deaths were among males.[@dyv117-B25] Hence, the sex-stratified estimates from Zimbabwe are not comparable with the estimates from the other RCTs.[@dyv117-B27] In the Ghana RCT, half of the mothers also received post-partum VAS[@dyv117-B11]---a policy which has now been abandoned.

The RCTs providing VAS between 1 and 11 months of age have generally found a less beneficial effect in females than in males ([Table 2](#dyv117-T2){ref-type="table"}, reviewed in[@dyv117-B28]).

#### Conclusion

The main body of evidence suggests that VAS in early infancy has a less beneficial effect for females than for males in settings with low HIV prevalence and no maternal VAS (the current policy). The evidence in older children is less clear; there were no strong sex differences in the older RCTs, but a recent RCT found that VAS to older children was better for females than for males.[@dyv117-B14] There is no indication that sex differences in VAD prevalence can explain these results.

### Vaccines

Many studies have shown that the live measles vaccine (MV, recommended at 9 months of age) is associated with strong beneficial effects on survival, which cannot be explained by prevention of measles infection, so-called non-specific effects.[@dyv117-B29] These effects are most pronounced for females. In contrast, though protective against the target diseases, the inactivated diphtheria-tetanus-pertussis vaccine (DTP, recommended at 6, 10 and 14 weeks of age) may have negative non-specific effects, increasing the mortality of females absolutely and relative to males (reviewed in[@dyv117-B32]). These trends, combined with the observation that VAS was associated with beneficial effect in children aged above 6 months but had no effect or even a tendency for a negative effect when given to children between 1 and 5 months of age, led us to propose the hypothesis that VAS amplifies the non-specific effects of vaccines, being beneficial in the context of MV, but harmful when given in the context of DTP vaccine.[@dyv117-B9] We asked for permission to test this hypothesis within RCTs in which vaccine data had been collected, or there was sufficiently high timely vaccination coverage to make reasonable assumptions about the participating children's vaccination status.

#### VAS above 6 months of age

We obtained permission to test our hypothesis in a re-analysis of one of the eight original VAS RCTs, the Ghana RCT. We found that VAS had only a beneficial effect in children with no record of vaccination at enrolment. Among vaccinated children, the effect of VAS differed between males and females, and VAS had a negative effect in measles-vaccinated females who were missing one or more doses of DTP at enrolment, but usually received these doses during follow-up.[@dyv117-B33]

Two observational studies from Guinea-Bissau have assessed the effect of VAS in campaigns in relation to vaccination status. In 2003, VAS was provided together with missing vaccines to children above 6 months of age, and children receiving VAS with DTP had 3.43 (95% CI 1.36-8.61) times higher mortality than those who received VAS alone, and 3.04 (1.31-7.07) times higher mortality than those who did not participate in the campaign.[@dyv117-B34] In two VAS campaigns in 2007 and 2008, the effect of VAS in children who had DTP vaccine as their last vaccine was worse than for children who had MV as their last vaccine.[@dyv117-B35]

Last, a RCT was conducted in Guinea-Bissau to test the effect of VAS provided at vaccination contacts. We hypothesized that compared with placebo, VAS with MV would be beneficial, particularly for females. We found the expected trend for females---both when MV was the only vaccine and when MV and DTP were given simultaneously---but surprisingly the opposite trend was seen for males. The interaction between VAS and sex was particularly pronounced in children who received DTP and MV simultaneously. We did not find support for the hypothesis that VAS provided with DTP was bad for females, but at least one-third of the DTP-vaccinated children received MV during the 6-month-follow-up and this may have masked the effect of VAS with DTP.[@dyv117-B14]

#### NVAS

The NVAS RCTs provided an additional possibility for testing the hypothesis of negative interaction between vitamin A and DTP vaccine, by testing the effect of NVAS vs placebo once the children start receiving DTP (around 6 weeks of age). In a combined analysis of the three NVAS trials from Guinea-Bissau,[@dyv117-B20]^,^[@dyv117-B36]^,^[@dyv117-B37] NVAS compared with placebo was associated with 63% (9-144%) increased mortality in females once they received DTP vaccine ([@dyv117-B38] and unpublished).

Unfortunately our request to test the hypothesis in the other NVAS RCTs with relevant data was declined, and for those RCTs we have had to rely on circumstantial evidence.

The Zimbabwean NVAS trial did not report results by vaccination status but, judged by the survival curves, NVAS was associated with increased mortality after the first months of life---just as seen in Guinea-Bissau and compatible with a negative interaction between NVAS and DTP vaccine.[@dyv117-B26] The Ghanaian trial reported that the effect of NVAS was 0.81 (95% CI 0.50-1.32) before the children received DTP-containing vaccines, but 1.36 (0.96-1.92) after DTP (*P* = 0.089 for interaction).[@dyv117-B12] In the Asian NVAS RCTs, vaccination coverage was lower and mortality was concentrated in the first months of life. Hence, a possible negative interaction between NVAS and subsequent DTP vaccine would be less apparent. Also, the non-specific effects of receiving first Bacillus Calmette--Guérin (BCG) and then DTP, as recommended by WHO, are quite different from receiving BCG and DTP at the same time; receiving BCG with DTP apparently ameliorates the negative effects of DTP in females.[@dyv117-B39] Hence, we would not expect NVAS followed by BCG + DTP, as often done in Asia,[@dyv117-B13] to be associated with negative effects in females similar to those of NVAS + BCG followed by DTP alone. Based on the Indian RCT from 2003, these authors published a separate paper on the potential non-specific effects of vaccines.[@dyv117-B42] Unfortunately, this paper eliminated the deaths in the first week of life, and the estimates for NVAS vs placebo by vaccination status cannot be deduced. The Indian 2014 RCT reported an analysis of mortality to 6 months of age by DTP vaccination status,[@dyv117-B13] but unfortunately the analysis suffered from severe survival bias and the results are not valid to draw conclusions from (Benn *et al*., Lancet, in press). The three new WHO-commissioned NVAS RCTs[@dyv117-B11] have not yet been analysed with respect to vaccines and sex but, in all three RCTs, NVAS was associated with increased female mortality in the second half of infancy, from 6-11 months \[meta-analysis estimate = 1.17 (0.98-1.40)\],[@dyv117-B11] compatible with a more negative effect in females after DTP vaccination.

In the Guinean NVAS RCTs, a subgroup of participants participated in an early MVRCT, being randomized to early MV or no such vaccine at 4.5 months of age. We would have predicted that NVAS would have a beneficial effect in the context of MV. However, we found that NVAS was associated with strong negative effects in children who received early MV, particularly so in males.[@dyv117-B29]^,^[@dyv117-B43] All children in the RCT had received the third DTP vaccine just 4 weeks prior to MV. This finding, and the finding that VAS was negative for males who received DTP and MV at the same time,[@dyv117-B14] indicate that the combination of NVAS and live and inactivated vaccines may be harmful for males.[@dyv117-B14]^,^[@dyv117-B43]

#### Conclusion

DTP has been associated with increased female mortality from non-targeted diseases, and most RCTs, backed by all available observational studies, suggest that VAS given close in time to DTP vaccine is associated with increased mortality, particularly in females.[@dyv117-B33] In contrast, VAS given close in time to MV may benefit females more than males[@dyv117-B14] ([Figure 3](#dyv117-F3){ref-type="fig"}). Interactions between vitamin A and vaccines hold the potential to explain why there were no strong sex differences and why VAS was more beneficial in the original eight RCTs conducted in the pre-vaccination era. It could also help explain why the African NVAS RCTs, conducted in urban settings with high vaccination coverage and sequential administration of BCG and DTP, have found more negative effects than the Asian NVAS RCTs conducted in predominantly rural areas with lower coverage and more BCG-DTP co-administration. Figure 3.Potential modification of vitamin A effects by vaccinations and repeated dosing.

### Repeated dosing of vitamin A

All studies which have reported data on the effect of the first vs subsequent doses of VAS by sex have found that a first dose of VAS may prime for a more beneficial response to subsequent VAS in females, but not in males.[@dyv117-B14]^,^[@dyv117-B35]^,^[@dyv117-B44]^,^[@dyv117-B45] This includes observational studies but also two RCTs ([Table 3](#dyv117-T3){ref-type="table"}). In the Guinea-Bissau RCT in children above 6 months of age, VAS vs placebo was associated with a mortality rate ratio (MRR) of 0.18 (0.05-0.62) in females who had received VAS on a previous occasion, but 0.82 (0.35-1.89) in those who had not (*P* = 0.05 for interaction between VAS and prior VAS). In males the opposite tendency was seen, reflected in a three-way interaction between VAS, sex and prior VAS (*P* = 0.007) ([Table 3](#dyv117-T3){ref-type="table"}).[@dyv117-B14] Table 3.The effect of repeated dosing with high-dose vitamin A supplementationAuthor, country and year of publicationGroupEffect of first doseEffect of second doseMortality rate ratioMortality rate ratio(95% CI)(95% CI)Fisker, Guinea-Bissau 2011[@dyv117-B44]Overall1.10 (0.64--1.90)0.54 (0.31--0.94)Males0.57 (0.23--1.42)0.73 (0.35--1.51)Females1.67 (0.81--3.42)0.37 (0.16--0.89)Fisker, Guinea-Bissau 2014[@dyv117-B1] [@dyv117-B4]Overall0.99 (0.57--1.77)0.80 (0.41--1.58)Males1.19 (0.53--2.65)5.98 (1.34--26.7)Females0.82 (0.35--1.89)0.18 (0.05--0.62)

The two original VAS RCTs which reported the effect by dosing round found better effect after subsequent doses of VAS. In Ghana, the mortality ratio after the first dose of VAS vs placebo was 0.99 (0.78-1.67) but declined to 0.68 (0.55--0.82) after subsequent doses.[@dyv117-B16] In Nepal, the mortality ratio was 0.76 (0.50-1.15) in the first 4 months of the study and 0.67 (0.63-0.73) in the subsequent rounds.[@dyv117-B46]

#### Conclusion

There is some evidence from both RCTs and observational studies to suggest that a first dose of VAS primes for a beneficial response to subsequent doses of VAS in females; in the Guinean RCT there was also some indication that males may be primed negatively. Hence, females may benefit more than males from repeated dosing of VAS ([Figure 3](#dyv117-F3){ref-type="fig"}), and this may explain some of the stronger beneficial effect of VAS seen in females after the first year of life.[@dyv117-B14] To our knowledge there are no data which contradict the hypothesis that a first dose of VAS primes for a more beneficial response to subsequent doses in girls.

### Length of follow-up

The outcome of potential effect modification by both prior VAS and subsequent vaccines would depend on the length of follow-up after VAS.

#### VAS above 6 months of age

The original VAS RCTs in children above 6 months of age almost all had follow-up for 12 months. The length of follow-up did not seem to play a major role.[@dyv117-B2]

#### NVAS

In all six African NVAS RCTs, the tendency for a negative effect of NVAS on overall mortality only became apparent after the first months of life. In the Asian RCTs, nearly all mortality occurred in the first 1-2 months of life and/or these studies only followed children to 6 months of age, apart from the India 2014 RCT. The beneficial effect was strongest in the first months of life in the Asian RCTs as well, and in the India 2014 RCT there was a more negative effect in the second part of infancy, as seen in the African RCTs.[@dyv117-B13]

#### Conclusion

The data from all RCTs are compatible with an increasingly negative effect of NVAS with increasing age/length of follow-up. This could be partly due to negative interaction with DTP vaccine. Thus, the length of follow-up is an important indicator of other exposures and could explain some of the heterogeneity in the NVAS RCTs, since the African NVAS RCTs had follow-up to 12--24 months whereas almost all the Asian NVAS RCTs only had follow-up to 4--6 months of age.

### Birthweight

#### NVAS

Potential effect modification by birthweight has been assessed in some of the NVAS trials. NVAS had an increasingly negative effect with increasing birthweight/ponderal index in Guinea-Bissau and Zimbabwe,[@dyv117-B20]^,^[@dyv117-B26]^,^[@dyv117-B36]^,^[@dyv117-B37] but not in Ghana.[@dyv117-B11] In the India 2003 RCT, the beneficial effect was limited to children with a low birthweight, but in contrast the most beneficial effect in Indonesia, India 2014 and to some extent Bangladesh was seen in the children weighing above 2500 g.[@dyv117-B13]^,^[@dyv117-B22]^,^[@dyv117-B47]

#### Conclusion

Low nutritional status indices may be associated with VAD and a better effect of VAS in the smallest children could be expected. However, this is not the case. In Guinea-Bissau, higher birthweight is also a marker of early DTP vaccination.[@dyv117-B40] This could help explain the observed negative interaction between NVAS and higher birthweight seen in many of the African RCTs. The observed inconsistent interaction between NVAS and birthweight is more likely to be explained by confounding factors.

### Season

Very few studies have addressed potential interaction between VAS and season, but in the Guinean RCTs it was done systematically. Guinea-Bissau has two quite distinct seasons, the dry season from December to May, and the rainy season from June to November.

#### VAS above 6 months of age

In the Guinea-Bissau RCT, the effect of VAS was not different in the dry \[MRR = 0.79 (0.43-1.45)\] and the rainy season \[MRR = 1.06 (0.56-2.02)\].[@dyv117-B14]

#### NVAS

One of the Guinean NVAS RCTs showed interaction between NVAS and season, the effect of NVAS being beneficial in the dry but not the rainy season.[@dyv117-B36] This finding was not corroborated, however, in the two subsequent RCTs.[@dyv117-B20]^,^[@dyv117-B37] In a small RCT, comparing NVAS with oral polio vaccine (OPV) in males only, the NVAS group experienced a cluster of deaths in the rainy season. However, due to the trial design it is not possible to say if this was caused by receiving NVAS or by not receiving OPV.[@dyv117-B48]

#### Conclusion

Season is a potential effect modifier of VAS, which could be studied retrospectively in existing datasets overall and by sex, and which should be considered in future studies. Season is an evident marker of differences in pathogen exposure, and clarification of the relationship between season and the effect of VAS could provide clues to understanding more about the biological mechanisms underlying the variable effects of VAS.

### Biological mechanisms

The results of the RCTs, which have been disappointing apart from the initial VAS RCTs in older children[@dyv117-B2] and a few RCTs in neonates in Asia,[@dyv117-B22]^,^[@dyv117-B23]^,^[@dyv117-B47] the lack of association between the degree of VAD and the effect of VAS, and the observed effect modifiers such as sex, vaccines and repeated doses of VAS (summarized in [Table 1](#dyv117-T1){ref-type="table"}) suggest that the effect of VAS may not merely be mediated by restoration of vitamin A levels. These high-dose supplements may have long-lasting imprinting effects on the immune system.[@dyv117-B49]

It is well described that vitamin A has several direct inhibitory short-term effects on the immune system. In line with this, vitamin A inhibits Th1 and Th17 responses, induces T regulatory cells, decreases pro-inflammatory cytokine production by the innate immune system and inhibits differentiation and maturation of monocytes into dendritic cells.[@dyv117-B50] In addition, it has recently been shown that ATRA (all-trans retinoic acid, the active metabolite of vitamin A) *in vitro* can induce epigenetic histone modifications in monocytes, leading to reduced gene transcription and down-regulated cytokine production.[@dyv117-B53] Epigenetic changes were long-lasting, raising the possibility that VAS could induce a long-term down-regulation of cytokine production by monocytes. Apart from histone modifications, changes in DNA methylation (another important epigenetic mark) could also play a causal role in the down-regulation of cytokine production, especially since ATRA in other cell types has been shown to be a regulator of DNA methylation. [@dyv117-B54]

The fact that BCG vaccination has opposite immunological effects to ATRA[@dyv117-B57] and is associated with strong reductions in all-cause mortality[@dyv117-B58]^,^[@dyv117-B59] indicates that VAS could have negative effects on the immune system, maybe contributing to increased all-cause mortality observed for certain subgroups, e.g. females who receive DTP after NVAS. However, in other subgroups VAS had no effect, or beneficial effects on mortality were observed. It could be speculated that these contradictory effects are due to differences in epigenetic modulation in the different subgroups. Also, a down-regulated innate immune response may be beneficial in situations in which infections induce immunopathology. This could have contributed to the very strong beneficial effect of VAS observed in many of the original studies, where the pathogen exposure may have been both different and heavier. This could also contribute to explaining the conflicting results of the NVAS trials done in different regions with presumably different pathogen exposure.

Modification of epigenetic marks is a complex process that is dependent on many factors and can be induced or undone during different clinical conditions. Research assessing epigenetic changes induced in the innate immune system by vitamin A or vaccinations is only beginning and many questions are still to be answered,[@dyv117-B60] but it seems plausible that the observed variable effect of VAS could at least partially be due to epigenetic modifications. It also seems plausible that the outcome of such modifications may differ depending on the state of the immune system and the clinical conditions and challenges it faces.[@dyv117-B61] Noteworthy, observed immunological interactions between ATRA and BCG *in vitro*[@dyv117-B53] and between NVAS and DTP in both animals[@dyv117-B62] and humans[@dyv117-B63] and between NVAS and early MV in humans[@dyv117-B64] supports the hypothesis that these interventions interact. Thus, the effect of VAS may differ depending on the vaccine programme in a country. For instance, the exposure and the sequence of vaccination with BCG and DTP differed considerably between the different NVAS trial sites and such differences may have contributed to the divergent results.[@dyv117-B49]

Discussion
==========

VAD is associated with increased mortality, and high-dose VAS has been assumed to reduce overall mortality in children between 6 months and 5 years of age by more than 20% by preventing VAD. However, we are facing an enigma. Two new RCTs have not found any effect on mortality.[@dyv117-B14]^,^[@dyv117-B15] In addition, RCTs providing VAS to younger children have had conflicting results; recently three WHO-commissioned NVAS RCTs hypothesized to find 15% reduction in overall mortality found no overall effect and even a tendency for negative effects in the two African RCTs.[@dyv117-B11]

In a situation with considerable heterogeneity of results in rigorously conducted RCTs, it is clear that there must be important effect modifiers. This review has identified several potential effect modifiers, which may help explain the heterogeneity: sex, vaccines and repeated doses of VAS may all influence the effect of VAS (summarized in [Table 1](#dyv117-T1){ref-type="table"}). In contrast, the effect did not differ in any systematic way by length of follow-up, birthweight or season.

To our knowledge we have presented all available data, with focus on data derived from RCTs, supported by observational studies where available. Unfortunately very few groups with the exception of ours have conducted subgroup analyses to explain the enigma. We have aimed to test our findings from subgroup analyses and the derived hypotheses in other groups' datasets. However, this has usually not been possible.A clear weakness of the present review is therefore that we have had to rely on circumstantial evidence, such as for instance DTP vaccination coverage being low in the Asian NVAS trials, rather than on the ideal evidence from a statistical analysis testing whether the effect of NVAS in the Asian trials differed by DTP vaccination status within the trial.

Indeed, recent immunological research has supported the conclusion that VAS has important immunological effects and may interact with other immune-modulatory interventions. The studies identified that both VAS and vaccines may induce long-lasting epigenetic modulations of the innate immune system. For instance, BCG vaccine is associated with an up-regulation of the innate immune response,[@dyv117-B57] whereas ATRA is associated with a down-regulation, and BCG and ATRA interacted.[@dyv117-B53] Thus, it is entirely plausible that interventions with effects on the immune system, such as vitamin A and vaccines, may interact biologically; in fact it would be surprising if they did not. It also seems plausible that many other factors which affect the immune system may also modify the effect of VAS.

In a recent paper it was suggested that the lack of effect of VAS in the recent Indian RCT in older children was caused by changes in disease pattern and because the high doses are not efficient at increasing serum retinol levels and reducing VAD. A policy shift was proposed, towards increasing frequent regular intake of vitamin A, replacing the high-dose supplements.[@dyv117-B65] The Micronutrient Initiative is making plans for down-scaling vitamin supplementation in countries which---according to vitamin A status data---may no longer be in need of biannual VAS.[@dyv117-B66] The Global Alliance for Vitamin A, GAVA, recommends continuing VAS until \< 5% of all children are suffering from VAD.[@dyv117-B67] These proposals are all based on the interpretation that VAS primarily works by preventing VAD.

It is unquestionablya good idea to improve the diet and increase the intake of vitamin A among children in low-income countries, but we think that the underlying idea that VAS is all about preventing VAD is too simplistic.[@dyv117-B68] Whereas there is no doubt that VAD leads to increased mortality and VAS can reduce VAD and improve health, VAS also affects the immune system, often in complex interactions with other factors which influence the immune system. As illustrated in [Figure 4](#dyv117-F4){ref-type="fig"}, VAS prevents VAD and this is probably always beneficial. However, depending on the effect of VAS on the immune system, the overall net effect of providing VAS can be much more beneficial than anticipated from the VAD-preventing effect. Some subgroups may benefit from VAS even if they are not suffering from VAD ([Figure 4](#dyv117-F4){ref-type="fig"}), and stopping high-dose VAS in favour of increased dietary intake may lead to increased mortality in these subgroups. On the other hand VAS can also be harmful, if negative effects on the immune system outweigh the benefits by preventing VAD ([Figure 4](#dyv117-F4){ref-type="fig"}). This is particularly likely to happen if the prevalence of VAD is low, and therefore it is worrying that GAVA recommends continuing VAS to all children until \< 5% of all children are suffering from VAD.[@dyv117-B67]^,^[@dyv117-B68] Figure 4.Vitamin A supplementation may affect both vitamin A status and immune function.

The negative RCTs have created an enigma---and that enigma obliges us to conduct more research and create optimal, evidence-based, vitamin A policies. In the first place, much can be gained by re-analysis of existing datasets. Second, although VAS to children above 6 months of age has been WHO policy for decades and RCTs have been judged unethical,[@dyv117-B69] the time has come for conducting new RCTs. Such RCTs should compare 4--6-monthly repeated high-dose VAS vs frequent low-dose VAS (for instance weekly doses) vs placebo. Since the vaccination programme has been the delivery channel for VAS in many countries, it would make sense to start by testing the effect of providing VAS with the first dose of MV at 9 months of age. Likewise RCTs of providing VAS with MV could be carried out in the countries that have introduced a second dose of MV in the second year of life. Ideally RCTs should be large-scale multi-centre trials, sized to assess potential effect modification by sex, vaccines and additional VAS. Only this way can we optimize the use of vitamin A, harvest the benefits and avoid harming some children.

This work was supported by the European Research Council (ERC-2009-StG, grant agreement no. 243149 to CSB). CVIVA is funded by the Danish National Research Foundation (DNRF108), which also paid the Open Access publication charges.

**Conflict of interest:** None declared.

[^1]: All major studies that have addressed the effect of vitamin A supplementation by sex. Some of the studies of children aged 12 months and older have also included younger children, but apart from Dr. Sommer's study it is not possible to extract the sex-specific mortality ratios for separate age groups.

[^2]: \*These trials were factorial trials with maternal supplementation as well.

[^3]: \*\*These trials had maternal supplementation programmes ongoing.

[^4]: \*\*\*The only trial which provided VAS with vaccines. Estimates by age group calculated by the authors.

[^5]: \#combined HIV positive and HIV negative cohort.
